FibroGen (NASDAQ:FGEN) Issues Earnings Results, Beats Estimates By $0.02 EPS

Share on StockTwits

FibroGen (NASDAQ:FGEN) announced its earnings results on Monday. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.02, Briefing.com reports. The firm had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. FibroGen had a net margin of 13.90% and a return on equity of 9.01%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.50) EPS.

Shares of FibroGen stock traded down $0.76 during trading hours on Tuesday, reaching $34.64. 26,941 shares of the company’s stock were exchanged, compared to its average volume of 810,108. The company has a 50 day moving average of $38.61 and a two-hundred day moving average of $41.88. FibroGen has a fifty-two week low of $33.51 and a fifty-two week high of $61.23. The company has a current ratio of 9.73, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The stock has a market cap of $3.62 billion, a P/E ratio of -33.86 and a beta of 1.84.

A number of equities analysts recently weighed in on FGEN shares. Mizuho reaffirmed a “positive” rating and issued a $72.00 target price (up from $65.00) on shares of FibroGen in a research note on Monday. ValuEngine raised shares of FibroGen from a “hold” rating to a “buy” rating in a research note on Friday. TheStreet raised shares of FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, Zacks Investment Research raised shares of FibroGen from a “hold” rating to a “buy” rating and set a $51.00 target price for the company in a research note on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. FibroGen currently has a consensus rating of “Buy” and an average price target of $58.33.

In other news, SVP Christine Chung sold 11,250 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $43.17, for a total transaction of $485,662.50. Following the completion of the transaction, the senior vice president now directly owns 157,195 shares in the company, valued at approximately $6,786,108.15. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $38.27, for a total transaction of $229,620.00. Following the transaction, the director now owns 34,400 shares of the company’s stock, valued at $1,316,488. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 86,756 shares of company stock valued at $3,644,083. Company insiders own 7.83% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Article: What are retained earnings?

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.